ISTH 2021

Roche-sponsored Virtual Symposium at ISTH 2021

Sunday, 18th of July 2021
12:30am - 13:30am (Eastern Time)


This session will take you from strategies and gaps in DOAC monitoring and solutions and challenges with the new Contact Pathway Inhibitors; to the gut microbiota, its effect on the hepatic endothelium and the emerging evidence of its link to the development of cardiovascular diseases and arterial thrombosis; as well as to the latest data of the ACTIV-4 trial and the efficacy of various anticoagulation strategies in COVID-19 thrombosis prevention and thromboinflammation management.

ISTH 2021


Sunday, 18th of July 2021
12:30am - 13:30am (Eastern Time)


From Basic Research to Clinical Data: the Future of Patient Management

Welcome and Introduction
Chair: Marcel Levi, London/UK

Measurement of Direct Oral Anticoagulants and Contact Pathway Inhibitors
Speaker: Jonathan Douxfils, Namur/Belgium

The gut Microbiota – an Actuating Variable in Arterial Thrombosis
Speaker: Christoph Reinhardt, Mainz/Germany

Thromboinflammation & Current RCT Data – are we Ready for the Future?
Speaker: Jean.M Connors, Boston/USA

Q&A, Session close
Chair: Marcel Levi, London/UK & all speakers

ISTH 2021

Meet the speakers

James Januzzi

Marcel Levi

London, UK


Prof. of Medicine, MD, PhD, FRCP


Marcel Levi is Professor of Medicine at University College London Hospitals and a practicing physician in acute medicine and hematology. Previously he was Dean of the Faculty of Medicine of the University of Amsterdam and Chief Executive of the Academic Medical Center in Amsterdam. He has published over 700 articles in scientific journals and has received a number of international research awards. He is currently chairman of the scientific board of several national charities, a board member of the National Cancer Institute and a member of the Royal Netherlands Academy of Science and Fellow of the Royal College of Physicians.

James Januzzi

Jonathan Douxfils

Namur, Belgium


PharmD, PhD


Prof Jonathan Douxfils is an academic at the University of Namur, Belgium, whose research has played a leading role in establishing well-recognized guidelines for the laboratory measurement of direct oral anticoagulants. He is also a pharmacovigilance expert at the European Medicines Agency, co-chairmen of the SSC Control of Anticoagulation at the International Society on Thrombosis and Haemostasis, a Member Expert Team Haemostasis Diagnostics at ECAT, and co-founder/CEO of the contract research organization, QUALIblood. Recently, he has received the Eberhard F. Mammen Young Investigator Award and was nominated as “Namurois of Year”, category Sciences, for his scientific engagement and discovery.

James Januzzi

Christoph Reinhardt

Mainz, Germany


Assoc. Professor


Christoph Reinhardt is an Associate Professor of Experimental Hemostasis and Gnotobiotics at the Center for Thrombosis and Hemostasis at University Medical Center, Johannes Gutenberg-University of Mainz, Germany. As part of his junior professorship, his research team established germ-free mouse isolator technology used to investigate molecular and cellular mechanisms acting on the vascular system through the microbial colonization of body surfaces, influencing the development of cardiovascular diseases. During his career, Assoc Prof Reinhardt has co-authored numerous scientific articles published in respected journals including Blood, Journal of Thrombosis and Haemostasis, Nature Medicine and Cell.

James Januzzi

Jean.M Connors

Boston, USA




Jean Connors is Medical Director of the Anticoagulation Management Service at Brigham and Women’s Hospital and Dana-Farber Cancer Institute, and an Associate Professor of Medicine at Harvard Medical School, Boston, MA. After receiving her MD from Johns Hopkins University, Baltimore, she completed a residency in internal medicine at Beth Israel Deaconess Medical Center, Boston, and fellowships in transfusion medicine and hematology/oncology from Brigham and Women’s Hospital. Dr Connors is an Associate Editor for the Journal of Thrombosis and Haemostasis and is involved in many professional societies. She is currently the PI for a NIH/NHLBI antithrombotics trial in COVID-19-positive outpatients.

pro-COAG 2021

pro-COAG 2021

Pro-COAG is a scientific and educational event, with world class experts, sharing and discussing current hot topics in the area of Coagulation.